Head-To-Head Comparison: Alphatec (NASDAQ:ATEC) versus LogicMark (OTCMKTS:LGMKD)

LogicMark (OTCMKTS:LGMKD) and Alphatec (NASDAQ:ATEC) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.

Valuation and Earnings

This table compares LogicMark and Alphatec”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LogicMark	$9.90 million	0.10	-$9.00 million	($94.52)	-0.01
Alphatec	$764.16 million	2.03	-$143.36 million	($0.71)	-14.13

LogicMark has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than LogicMark, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

LogicMark has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500. Comparatively, Alphatec has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500.

Institutional & Insider Ownership

7.9% of LogicMark shares are owned by institutional investors. Comparatively, 66.3% of Alphatec shares are owned by institutional investors. 2.2% of LogicMark shares are owned by company insiders. Comparatively, 13.5% of Alphatec shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares LogicMark and Alphatec’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LogicMark	-90.21%	-57.08%	-44.90%
Alphatec	-13.49%	-6,752.24%	-13.88%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for LogicMark and Alphatec, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LogicMark	0	1	0	0	2.00
Alphatec	1	1	13	0	2.80

Alphatec has a consensus target price of $17.40, indicating a potential upside of 73.48%. Given Alphatec’s stronger consensus rating and higher probable upside, analysts clearly believe Alphatec is more favorable than LogicMark.

Summary

Alphatec beats LogicMark on 10 of the 14 factors compared between the two stocks.

About LogicMark

LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company’s devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one’s health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.

About Alphatec

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec surface modifications, Calibrate PSX, and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold for ease of handling and better endplate-to-endplate contact; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissues; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.